BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 16516670)

  • 1. Clinical experience with denileukin diftitox (ONTAK).
    Foss F
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S11-6. PubMed ID: 16516670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denileukin diftitox: a concise clinical review.
    Eklund JW; Kuzel TM
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):33-8. PubMed ID: 15757436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing denileukin diftitox (Ontak) therapy.
    Duvic M; Talpur R
    Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
    Wong BY; Gregory SA; Dang NH
    Cancer Invest; 2007 Sep; 25(6):495-501. PubMed ID: 17882663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
    Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
    J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
    Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
    J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders.
    Turturro F
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):11-7. PubMed ID: 17187516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
    Walker PL; Dang NH
    Clin J Oncol Nurs; 2004 Apr; 8(2):169-74. PubMed ID: 15108419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denileukin diftitox: a novel immunotoxin.
    Manoukian G; Hagemeister F
    Expert Opin Biol Ther; 2009 Nov; 9(11):1445-51. PubMed ID: 19817678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission.
    Wong BY; Ma Y; Fitzwilson R; Dang NH
    Am J Hematol; 2008 Jul; 83(7):596-8. PubMed ID: 18383317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denileukin diftitox.
    Figgitt DP; Lamb HM; Goa KL
    Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
    Chin KM; Foss FM
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
    LeMaistre CF
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
    Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
    Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
    Olsen E; Duvic M; Frankel A; Kim Y; Martin A; Vonderheid E; Jegasothy B; Wood G; Gordon M; Heald P; Oseroff A; Pinter-Brown L; Bowen G; Kuzel T; Fivenson D; Foss F; Glode M; Molina A; Knobler E; Stewart S; Cooper K; Stevens S; Craig F; Reuben J; Bacha P; Nichols J
    J Clin Oncol; 2001 Jan; 19(2):376-88. PubMed ID: 11208829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.
    Kerl K; Prins C; Cerroni L; French LE
    Br J Dermatol; 2006 May; 154(5):988-91. PubMed ID: 16634908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
    Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
    J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.
    Avarbock AB; Loren AW; Park JY; Junkins-Hopkins JM; Choi J; Litzky LA; Rook AH
    Am J Hematol; 2008 Jul; 83(7):593-5. PubMed ID: 18335564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denileukin diftitox.
    Saxon M
    Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
    Foss FM
    Clin Lymphoma; 2000 Sep; 1(2):110-6; discussion 117. PubMed ID: 11707818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.